25 results
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
Women with in HIV-AIDS ... #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
Infections in HIV-AIDS ... #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Toxoplasma gondii Encephalitis in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
 •
Encephalitis in HIV-AIDS ... #Treatment #opportunistic ... #infections #HIVAIDS ... #management #pharmacology ... #pharmacology
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
Trypanosomiasis) in HIV-AIDS ... #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
Infections in HIV-AIDS ... #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Bartonella Infections in HIV-AIDS
Preferred Therapy
For Bacillary Angiomatosis, Peliosis Hepatis, Bacteremia, and Osteomyelitis:
Infections in HIV-AIDS ... #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Herpes Simplex Virus (HSV) Infections in HIV-AIDS
Treating Orolabial Lesions (Duration: 5–10 days)
Infections in HIV-AIDS ... #IDSA #Prevention ... #Treatment #management ... #opportunistic ... #pharmacology
IDSA Recommendations for Preventing and Treating HHV-8 Diseases—Kaposi Sarcoma (KS), Primary Effusion Lymphoma (PEL), Multicentric Castleman’s
Disease (MCD) in HIV-AIDS ... #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
Leishmaniasis in HIV-AIDS ... #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
Candidiasis in HIV-AIDS ... #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology